Figure 2.

Supplementation with NAD⁺de novo precursors reverses NAD⁺-dependent phenotypes. A, ratio of tdo-2 mRNA levels in pnc-1(pk9605) mutants and N2 controls. tdo-2 encodes the enzyme that catalyzes the rate-limiting step in the kynurenine pathway. *, 0.01 < p < 0.05, calculated with Student's t test. B, supplementation of 20 mm QA, Kyn, and 3HAA to pnc-1(pk9605) mutants restores the gonad developmental delay. For histograms, error bars are S.D. **, 0.001 < p < 0.01; ***, p < 0.001; calculated with Fisher's exact test. C, supplementation of 20 mm QA to pnc-1(pk9605) mutants restores NAD⁺ levels. LC-MS measurements of relative levels of NAD⁺ and in N2 and pnc-1(pk9605) mutant. Plots are described in legend to Fig. 1B. *, 0.01 < p < 0.05; calculated with Welch's two sample t test.